Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $21.49

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) shares gapped down before the market opened on Thursday . The stock had previously closed at $21.49, but opened at $21.01. Calliditas Therapeutics AB (publ) shares last traded at $21.01, with a volume of 313 shares changing hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Trading Down 2.2 %

The company has a quick ratio of 3.08, a current ratio of 3.13 and a debt-to-equity ratio of 2.89. The firm’s fifty day moving average price is $21.78 and its 200-day moving average price is $20.24.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02. The business had revenue of $42.45 million for the quarter, compared to analysts’ expectations of $36.24 million. Calliditas Therapeutics AB (publ) had a negative net margin of 38.72% and a negative return on equity of 104.47%. During the same quarter in the previous year, the business posted ($0.01) earnings per share. As a group, analysts predict that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Institutional Trading of Calliditas Therapeutics AB (publ)

Large investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG boosted its holdings in shares of Calliditas Therapeutics AB (publ) by 26.5% during the 1st quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock valued at $2,170,000 after buying an additional 18,978 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Calliditas Therapeutics AB (publ) during the 1st quarter valued at $221,000. Tower Research Capital LLC TRC boosted its holdings in shares of Calliditas Therapeutics AB (publ) by 1,270.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock valued at $51,000 after buying an additional 3,112 shares in the last quarter. Finally, Optiver Holding B.V. purchased a new position in shares of Calliditas Therapeutics AB (publ) in the 4th quarter worth about $25,000. Institutional investors own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.